Related Experiment Video
Updated: Jan 2, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited
Allan Buzibye1, Joseph Musaazi2, Amrei von Braun3
1Infectious Diseases Institute, Makerere University, College of Health Sciences, P. O. BOX 22418, Kampala, Uganda. abuzibye@idi.co.ug.
Background:
Several studies demonstrate a correlation between sub-therapeutic concentrations of antiretroviral drugs and virologic failure. We examined the sensitivity, specificity and predictive values of sub-therapeutic drug levels in predicting viralogic failure.
Methods:
This was a case control study with cases being samples of participants with virologic failure, and controls samples of participants with virologic suppression. We analyzed samples obtained from participants that had been on antiretroviral treatment (ART) for at least 6 months. Virologic failure was defined as HIV-RNA viral load ≥ 1000 copies/ml. Sub-therapeutic drug levels were defined according to published reference cutoffs. The diagnostic validity of drug levels for virologic failure was assessed using plasma viral loads as a gold standard.
Results:
Sub-therapeutic ART concentrations explained only 38.2% of virologic failure with a probability of experiencing virologic failure of 0.66 in a patient with low drug levels versus 0.25 for participants with measurements within or above the normal range. Approximately 90% of participants with ART concentrations above the lower clinical cut off did not have virologic failure.
Conclusions:
These results support prior indication for therapeutic drug monitoring in cases of suspected virologic failure.
More Related Videos
23:56Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
13:58Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
Published on: September 26, 2011
Related Concept Videos
Retrovirus Life Cycles
Therapeutic Drug Monitoring: Affecting Factors